Skip to main content
SpringerLink
Log in

Pharmacoeconomic Evaluation of Lenograstim

Conclusions and Future Directions

  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

To evaluate the safety and efficacy of lenograstim, a new recombinant human granulocyte colony-stimulating factor (rHuG-CSF), as an adjunct to cancer chemotherapy, 3 phase III randomised clinical trials were recently conducted in Europe in patients with inflammatory breast cancer, non-Hodgkin’s lymphoma, and small cell lung cancer. To explore the economic implications of lenograstim therapy, a multinational pharmacoeconomics programme was undertaken using data collected during these clinical trials. This programme consisted of concurrent prospective economic evaluations undertaken by study teams in France (non-Hodgkin’s lymphoma), Germany and Italy (a combined evaluation in inflammatory breast cancer) and the UK (small cell lung cancer). In these studies, attention was focused on the direct costs of medical care —principally the costs of cancer chemotherapy as well as its associated morbidity. In 2 of the pharmacoeconomic evaluations (i.e. the French, German/Italian), lenograstim was found to generate cost savings as a result of reductions in morbidity associated with chemotherapy. However, the cost of lenograstim therapy would be likely to exceed these savings, leading to an overall increase in the costs of cancer treatment. Whether the use of lenograstim is cost-effective will therefore largely depend on its impact on patient survival and quality of life, and current practical use. These issues are the focus of additional clinical studies currently underway. In addition, new research is focusing on the clinical benefits of lenograstim in other areas of oncology and haematology. Further pharmacoeconomic studies in these areas are also warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mapelli V, Schulenburg J-M, Laaser U, et al. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy. PharmacoEconomics 1994; 6 Suppl. 2: 27–35

    Article  PubMed  Google Scholar 

  2. Souêtre E, Qing W. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin’s lymphoma. PharmacoEconomics 1994; 6 Suppl. 2: 36–43

    Article  PubMed  Google Scholar 

  3. Gisselbrecht C, Lepage E, Haloun IC, et al. Lenograstim (glycosylated recombinant human G-CSF) supported chemotherapy optimisation in aggressive non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 1993; 12: 363

    Google Scholar 

  4. Drummond M, Davies L. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer. PharmacoEconomics 1994; 6 Suppl. 2: 44–52

    Article  PubMed  Google Scholar 

  5. Marty M. The optimal dose of glycosylated rHuG-CSF for use in clinical practice. Eur J Cancer 1994. In press

  6. Williams SF, Mick R, Desser R, et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824–30

    PubMed  CAS  Google Scholar 

  7. Dunphy FR, Spitzer G, Elias A, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–16

    PubMed  CAS  Google Scholar 

  8. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiopeta and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–10

    PubMed  CAS  Google Scholar 

  9. Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer. A feasibility study. J Clin Oncol 1994; 12: 37–44

    CAS  Google Scholar 

  10. Sheridan WP, Fox RM. Haematopoietic growth factors and cancer therapy. Med J Aust 1993; 158: 514–5

    PubMed  CAS  Google Scholar 

  11. Glaspy JA, Jakway J. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm 1993; 50 Suppl. 3: S19–26

    PubMed  CAS  Google Scholar 

  12. Bregni M, Magni M, Siena S, et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral gene transfer. Blood 1992; 80: 1418–22

    PubMed  CAS  Google Scholar 

  13. Klingemann HG, Faves AC, Barnett MJ, et al. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin Invest Med 1990; 13: 77–81

    PubMed  CAS  Google Scholar 

  14. Demuynck H, Verhoef GEG, Zachee P, et al. Interleukin 3 in graft failure post bone marrow transplantation. Proc Belg Soc Hematol 1993; 8: 51

    Google Scholar 

  15. Ohno R, Tomonaga M, Robayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Eng J Med 1993; 323: 871–77

    Article  Google Scholar 

  16. Dombret H, Yver A, Chastang C, et al. European multicentre phase III randomized placebo-controlled study of lenograstim (recombinant glycosylated human G-CSF) in elderly patients with de novo acute myeloid leukaemia (AML) [abstract no. 601]. Br J Haematol 1994; 87 Suppl. 1: 154

    Google Scholar 

  17. Champlin RE, Nimer SD, Ireland P, et al. Treatment of refractory aplastic anaemia with recombinant human granulocytemachrophage colony stimulating factor. Blood 1989; 73: 694–699

    PubMed  CAS  Google Scholar 

  18. Kojima S, Fukuda M, Miyajima T, et al. Treatment of aplastic anaemia in children with granulocyte colony stimulating factor. Blood 1991; 77: 937–41

    PubMed  CAS  Google Scholar 

  19. Groopman JE, Feder D. Haematopoietic growth factors in AIDS. Semin Oncol 1992; 19: 408–14

    PubMed  CAS  Google Scholar 

  20. Hengge UR, Brockmeyer NH, Goos M. G-CSF in AIDS patients. Clin Invest 1992; 70: 922–26

    Article  CAS  Google Scholar 

  21. Grossberg H, Bonnern E, Buhles W. GH-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. N Eng J Med 1989; 320: 1560

    CAS  Google Scholar 

  22. Demuynck H, Zanchee P, Verhoef G, et al. G-CSF treatment for drug-induced agranulocytosis. Br J Haematol. In press

  23. Grogan JB. Altered neutrophil phagocytic function in burn patients. J Trauma 1976; 16: 734–8

    Article  PubMed  CAS  Google Scholar 

  24. Wilson RM. Infection in diabetes. In: Pickup J, Williams G, editors. Textbook of diabetes. Oxford: Blackwell, 1991: 813–19

    Google Scholar 

  25. Goldstein R, Bowen D, Fauci AS. Adrenal corticosteroids. In: Gallin JI, et al., editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992: 1061–81

    Google Scholar 

  26. Raahave D. Wound contamination and postoperative infection. In: Taylor E, editor. Infection in surgical practice. Oxford: Oxford University Press 1992: 49–55

    Google Scholar 

  27. Donadieu J, Boutard P, Tchernia G, et al. A phase II study of recombinant human granulocyte colony-stimulating factor (rHuG-CSF; lenograstim) in the treatment of agranulocytosis in children. Nouv Rev Fr Hematol. In press

  28. Chao N, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor ‘mobilised’ peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81(8): 2031–5

    PubMed  CAS  Google Scholar 

  29. Cleary PD, Morrisey G, Yver A, et al. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis. Quality of Life Research. In press

  30. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994; 12(6): 1245–50

    PubMed  CAS  Google Scholar 

  31. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325(3): 164–70

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Policy Analysis Inc., Four Davis Court, Brookline, Massachusetts, 02146, USA

    Joseph Menzin & Gerry Oster

  2. Chugai-Rhône-Poulenc, Antony, France

    Veronique Cour-Chabernaud & Denise Richard

Authors
  1. Joseph Menzin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerry Oster
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Veronique Cour-Chabernaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Denise Richard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Menzin, J., Oster, G., Cour-Chabernaud, V. et al. Pharmacoeconomic Evaluation of Lenograstim. Pharmacoeconomics 6 (Suppl 2), 53–60 (1994). https://doi.org/10.2165/00019053-199400062-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199400062-00009

Keywords

Search

Navigation